title: Gene therapy for ovarian cancer.
abstract: Ovarian cancer remains the leading cause of death due to gynecologic cancer in women in the United States. Gene and viral-based therapies represent novel therapeutic approaches for cancer. The manipulation of genetic content of tumor cells toward a therapeutic end has been divided into several general strategies, including molecular chemotherapy, mutation compensation, immunopotentiation, and virotherapy. Improvements in delivery vehicles and in evaluation of gene transfer and viral replication remain important areas of investigation. We highlight the most recent advances in these novel therapeutic approaches for ovarian cancer and include a summary of recent clinical trials.
authors.affiliation: Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
authors.forename: Kristopher J
authors.initials: KJ
authors.lastname: Kimball
authors.forename: T Michael
authors.initials: TM
authors.lastname: Numnum
authors.forename: Rodney P
authors.initials: RP
authors.lastname: Rocconi
authors.forename: Ronald D
authors.initials: RD
authors.lastname: Alvarez
mesh_terms: D000276:Adjuvants, Immunologic / Q000235:genetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D018390:Gene Targeting; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000502:physiology; D006801:Humans; D008954:Models, Biological; D050130:Oncolytic Virotherapy / Q000379:methods; D010051:Ovarian Neoplasms / Q000628:therapy*; D014779:Virus Replication / Q000502:physiology
chemical_list: D000276:Adjuvants, Immunologic